Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthofix Medical (OFIX) Research & Development (2016 - 2025)

Orthofix Medical's Research & Development history spans 16 years, with the latest figure at $15.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 18.26% year-over-year to $15.4 million, compared with a TTM value of $65.8 million through Dec 2025, down 10.59%, and an annual FY2025 reading of $65.8 million, down 10.59% over the prior year.
  • Research & Development for Q4 2025 was $15.4 million at Orthofix Medical, up from $14.8 million in the prior quarter.
  • The five-year high for Research & Development was $23.3 million in Q1 2023, with the low at $10.9 million in Q1 2021.
  • Average Research & Development over 5 years is $15.9 million, with a median of $15.7 million recorded in 2025.
  • Year-over-year, Research & Development skyrocketed 107.88% in 2023 and then dropped 18.26% in 2025.
  • Tracing OFIX's Research & Development over 5 years: stood at $13.2 million in 2021, then decreased by 0.69% to $13.2 million in 2022, then soared by 44.02% to $18.9 million in 2023, then decreased by 0.7% to $18.8 million in 2024, then dropped by 18.26% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's Research & Development are $15.4 million (Q4 2025), $14.8 million (Q3 2025), and $15.9 million (Q2 2025).